Real CCRP dumps - Real SOCRA dumps PDF in here [Jul-2026]
Realistic TrainingDumps CCRP Dumps PDF - 100% Passing Guarantee
SOCRA CCRP Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
NEW QUESTION # 42
An investigator received an updated investigator's brochure from the sponsor; the update did not include changes related to subject safety. Which of the following parties, if any, is the investigator required to notify?
- A. The IRB/IEC
- B. The Data Safety Monitoring Board (DSMB)
- C. No notification is required
- D. The regulatory authority
Answer: C
Explanation:
TheInvestigator's Brochure (IB)is updated by the sponsor to reflect new scientific or clinical information.
* ICH E6(R2) 7.3:"The sponsor should revise the IB as soon as new, significant information becomes available."
* ICH E6(R2) 4.1.5:Requires the investigator to ensure staff are informed, but there isno requirementto notify IRB/IEC unless subject safety, rights, or risk profile is affected.
Since this update containedno changes related to subject safety, the investigator is not obligated to notify IRB/IEC, DSMB, or regulators. The updated IB must simply be filed in theregulatory binderand implemented at the site.
Thus, the correct answer isD (No notification is required).
References:
ICH E6(R2), §7.3 (Updating the Investigator's Brochure).
ICH E6(R2), §4.1.5 (Investigator responsibilities for informing staff).
NEW QUESTION # 43
In accordance with ICH/GCP Guidance, how long should an IRB/IEC retain all relevant study-related records pertaining to the IRB/IEC's review after a trial has been completed?
- A. Until the regulatory authority has approved the investigational product for use
- B. Indefinitely
- C. At least 3 years
- D. At least 15 years
Answer: C
Explanation:
IRBs/IECs must retain records to permit evaluation of compliance.
* ICH E6(R2) 3.4.2:"IRB/IEC should retain all relevant records (e.g., written procedures, membership lists, lists of occupations/affiliations of members, submitted documents, minutes of meetings, and correspondence) for at least3 years after completion of the trial." Extended retention (B-D) may occur institutionally, but ICH minimum is3 years.
Correct answer:A (At least 3 years).
References:
ICH E6(R2), §3.4.2.
NEW QUESTION # 44
Which of the following is one of the responsibilities of an investigator who is NOT a sponsor?
- A. Maintaining control of the investigational product
- B. Ensuring that all participating investigators are promptly informed of significant new adverse events
- C. Ensuring proper monitoring of an investigation at all investigational sites
- D. Reporting serious adverse events to the applicable regulatory agency
Answer: A
Explanation:
For non-sponsor investigators, responsibilities are limited tosite-level conduct and product accountability.
* ICH E6(R2) 4.6.1:"Responsibility for investigational product(s) accountability at the trial site rests with the investigator/institution."
* 21 CFR 312.61:Requires the investigator to administer investigational drugs only to subjects under their supervision and maintain control.
Other responsibilities listed belong tosponsors:
* A: Reporting SAEs to FDA is a sponsor duty (investigators report to sponsor, not directly to FDA).
* B: Monitoring at all sites is a sponsor responsibility.
* C: Disseminating safety updates is a sponsor's role.
Correct answer:D (Maintaining control of IP).
References:
ICH E6(R2), §4.6.1.
21 CFR 312.61.
NEW QUESTION # 45
An unconscious patient experiencing life-threatening cardiac arrhythmias has been admitted to an emergency room. No FDA-approved treatment is available, and no legal representative is present. The clinical investigator determined that the use of an investigational antiarrhythmic drug is required. In accordance with the CFR, who must certify the investigator's determination?
- A. An independent physician
- B. The sponsor's study monitor
- C. The sponsor's medical monitor
- D. A sub-investigator
Answer: A
Explanation:
This scenario falls underemergency use of investigational drugs without informed consent.
* 21 CFR 50.23(a):Allows waiver of informed consent if subject faces a life-threatening condition, available treatments are unproven, and immediate use is required.
* 21 CFR 50.23(a)(3):Requires that "the determination... be reviewed and concurred with by a physician who is not otherwise participating in the clinical investigation." Thus, anindependent physician(not part of the trial team) must certify the necessity of emergency investigational use.
Sponsors and monitors (C, D) are not authorized by regulation to make such determinations. Sub-investigators (A) lack independence and would be conflicted.
Correct answer:B (Independent physician).
References:
21 CFR 50.23(a)(3).
NEW QUESTION # 46
During an internal compliance review, the site study team identified that a protocol-required blood sample collection was not obtained for a majority of the subjects enrolled. In accordance with the ICH GCP Guideline, the clinical investigator should:
- A. Suspend all trial-related activities until the events of the deviation have been mitigated
- B. Immediately report the observation to the regulatory authority
- C. Document and explain the deviation from the protocol
- D. Assign another investigator to perform sample collections until an internal investigation is completed
Answer: C
Explanation:
ICH directs investigators todocument and explainany deviation, with prompt reporting to IRB/IEC only when deviations are implemented to eliminate immediate hazards or as required. Exact extracts:
* ICH E6(R2) 4.5.3: "The investigator should document and explain any deviationfrom the approved protocol."
* ICH E6(R2) 3.3.7 & 4.5.2 (paraphrased): deviations to eliminate immediate hazards must be reported as soon as possible.Here, absent immediate hazard, the required action is documentation and explanation (B).
References:
ICH E6(R2) Good Clinical Practice, §4.5.3 (Compliance with protocol; deviations).
ICH E6(R2) §3.3.7; §4.5.2 (Reporting deviations implemented to eliminate immediate hazards).
NEW QUESTION # 47
In accordance with 21 CFR Part 11, a closed electronic records system must do all EXCEPT:
- A. Print a complete paper copy
- B. Maintain accurate records throughout retention
- C. Customize access rights
- D. Generate audit trails
Answer: A
Explanation:
* 21 CFR 11.10:Requires validation, audit trails, secure access, but does not mandate printing capability.
Thus, (D) is the exception.
References:21 CFR 11.10.
NEW QUESTION # 48
A subject currently on a clinical trial was hospitalized for 2 days due to a SAE. The subject reported the hospitalization to the investigator at the next study visit. According to the ICH GCP Guideline, when should the investigator report the SAE to the sponsor?
- A. Within 7 working days
- B. Immediately
- C. Within 10 working days
- D. Within 15 working days
Answer: B
Explanation:
ICH requiresimmediatereporting of all SAEs to the sponsor (except those protocol-identified as not requiring immediate reporting). Exact extract:
* ICH E6(R2) 4.11.1: "The investigatorshould report all serious adverse events immediately to the sponsorexcept for those SAEs that the protocol... identifies as not needing immediate reporting." Therefore, "Immediately" (A) is correct. The other timeframes are not aligned with ICH GCP for initial SAE notification from investigator to sponsor.
References:
ICH E6(R2) Good Clinical Practice, §4.11.1 (Safety reporting by investigators).===========
NEW QUESTION # 49
According to ICH GCP, sponsor-specific essential documents must be retained until:
- A. 3 years after last approval
- B. 25 years after last approval
- C. 2 years after last approval and no pending applications
- D. 5 years after last approval
Answer: C
Explanation:
* ICH E6(R2) 5.5.12 & 8.1:Essential documents must be retained2 years after the last approval of a marketing application in an ICH region and until no applications are pending, or2 years after discontinuation of development.
This ensures availability for inspection.
References:ICH E6(R2) §§5.5.12, 8.1.
NEW QUESTION # 50
An investigator received an updated informed consent form (ICF) from the sponsor for a study closed to enrollment. Subjects are only in long-term follow-up. The change related to frequent radiation imaging at screening, with no change to drug safety profile. Who must the investigator notify first?
- A. Participants in long-term follow-up
- B. No notification is required
- C. The IRB/IEC
- D. Sub-investigators
Answer: C
Explanation:
* 21 CFR 56.109(a):IRBs must review all changes to informed consent before implementation.
* ICH E6(R2) 4.8.2:If new information could affect willingness to continue, consent forms must be revised and approved by the IRB.
Even though screening is closed, the IRB/IEC must review the updated form before any subject re-consenting.
References:21 CFR 56.109(a); ICH E6(R2) §4.8.2.
NEW QUESTION # 51
A physician wants to conduct research using an approved/marketed cardiac stent for use in the carotid artery, which is not an indication for which the device is approved. In this case, the physician must obtain which of the following?
- A. IRB/IEC and manufacturer approval
- B. IRB/IEC approval and an FDA IDE
- C. The Office for Human Research Protections (OHRP) and manufacturer approvals
- D. IRB/IEC approval and an FDA IND
Answer: B
Explanation:
When a physician investigates amedical device for a new use (off-label indication), FDA regulations classify this as aSignificant Risk Device Study, requiring anInvestigational Device Exemption (IDE)in addition to IRB approval.
* 21 CFR 812.20(a):"A sponsor shall submit an application to FDA for aninvestigational device exemption (IDE)if the device is to be used in a clinical investigation to determine safety and effectiveness."
* 21 CFR 812.2(b):Significant Risk device studies requireboth FDA and IRB approvalbefore initiation.
An IND (B) applies to drugs and biologics, not devices. Manufacturer permission (A, D) is not a regulatory requirement, although collaboration may be necessary. OHRP approval is not applicable.
Thus, the correct answer isC (IRB/IEC approval and an FDA IDE).
References:
21 CFR 812.20(a) (IDE submission requirements).
21 CFR 812.2(b) (Significant risk device studies).
NEW QUESTION # 52
In accordance with the Belmont Report, obtaining voluntary informed consent from subjects prior to enrolling them in a clinical trial is an example of which of the following ethical principles?
- A. Respect for persons
- B. Justice
- C. Beneficence
- D. Do no harm
Answer: A
Explanation:
TheBelmont Report (1979)establishedthree key ethical principles:
* Respect for Persons:Requires informed consent, recognition of autonomy, and protection of vulnerable individuals.
* Beneficence:Obligation to maximize benefits and minimize harm.
* Justice:Ensuring fairness in subject selection and distribution of research burdens/benefits.
Voluntary informed consent embodiesRespect for Persons, as subjects are given adequate information and freedom of choice. "Do no harm" (A) is a Hippocratic principle but not Belmont terminology.
Thus, the correct answer isB (Respect for persons).
References:
The Belmont Report (1979), Part B: Basic Ethical Principles.
NEW QUESTION # 53
In accordance with 45 CFR 46, in addition to the Office for Human Research Protections (OHRP), a suspension of IRB/IEC approval must be reported to which of the following?
- A. The appropriate institutional officials
- B. The local hospital's bioethics committee
- C. The local hospital's medical director
- D. The Scientific Review Committee
Answer: A
Explanation:
If IRB/IEC approval is suspended or terminated, reporting is required to protect oversight and accountability.
* 45 CFR 46.113:"An IRB shall notify theinstitutional officials, the department or agency head, and OHRP(when applicable) of any suspension or termination of IRB approval." This ensures transparency and institutional responsibility for compliance. Internal hospital committees or directors (A, C, D) are not mandated reporting entities.
Thus, the correct answer isB (Appropriate institutional officials).
References:
45 CFR 46.113 (Suspension or termination of IRB approval).
NEW QUESTION # 54
According to the CFR, when children who are wards of the state are enrolled into a clinical trial, what is required?
- A. The investigator must represent the children
- B. Each child must have a patient advocate
- C. The IRB/IEC must include a member who advocates for the children
- D. Assenting children must self-represent
Answer: C
Explanation:
Children who are wards of the state receiveadditional protectionsin clinical research.
* 45 CFR 46.409(b):For research involving wards, "the IRB shall require appointment of an advocate for each child, in addition to any guardian or other advocate who would ordinarily be provided."
* The advocate must have background and experience to act in the child's best interest and cannot be associated with the research.
Thus, anIRB-appointed advocateis mandatory to ensure independent representation of the ward's rights.
References:45 CFR 46.409(b).
NEW QUESTION # 55
A sponsor's monitor is conducting a site selection visit for an interventional drug trial. In accordance with ICH GCP, which pharmacy drug storage facility information should be collected in order to determine whether the site could be selected for the trial?
- A. Storage facility temperature range
- B. Number of staff members
- C. Available storage square footage
- D. Storage cost
Answer: A
Explanation:
Drug storage conditions are essential to maintaining investigational product (IP) integrity. According to ICH:
* ICH E6(R2) 5.13.3:"The sponsor should ensure that investigational products are stored... under appropriate conditions as specified by the sponsor and in accordance with applicable regulatory requirement(s)."
* ICH E6(R2) 4.6.4:"The investigator/institution should store the investigational product(s) as specified by the sponsor (and in accordance with applicable regulatory requirement(s)), and ensure that product (s) are used only in accordance with the approved protocol." During site qualification/selection, the monitor evaluates storage conditions - particularlytemperature ranges- to ensure the site can meet the stability requirements for the IP. Factors like staff numbers, space, and cost are operational considerations but not regulatory determinants of site qualification.
Thus, the correct answer isC (Storage facility temperature range). This ensures compliance with sponsor specifications, product stability, and ultimately subject safety.
References:
ICH E6(R2), §5.13.3 (Product storage requirements).
ICH E6(R2), §4.6.4 (Investigator product storage responsibilities).
NEW QUESTION # 56
A sponsor-investigator implemented a protocol deviation in a device trial to eliminate an immediate hazard.
Before applying this change to all subjects, what must occur?
- A. Document change in study file
- B. Obtain IRB/IEC approval
- C. Inform all subjects
- D. Train sub-investigators
Answer: B
Explanation:
* 21 CFR 812.35(a)(2):Allows deviation without prior approval only to eliminate immediate hazards.
* Before applying broadly,IRB approvalmust be obtained.
References:21 CFR 812.35(a)(2).
NEW QUESTION # 57
After randomization, investigational drug is shipped to site. Who is responsible for accountability?
- A. Investigator
- B. Investigational pharmacist
- C. Research coordinator
- D. Sponsor
Answer: A
Explanation:
* ICH E6(R2) 4.6.1:"Responsibility for investigational product accountability at the trial site rests with the investigator."
* May delegate to pharmacist or coordinator, butultimate responsibilitylies with investigator.
References:ICH E6(R2) §4.6.1.
NEW QUESTION # 58
......
Verified CCRP dumps Q&As Latest CCRP Download: https://vcecollection.trainingdumps.com/CCRP-valid-vce-dumps.html
